Julie A. Ressler

City of Hope — United States

Medicine · Health Sciences

13h-index15.2kcitations48works49.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(31), Immunotherapy and Immune Responses(14), Glioma Diagnosis and Treatment(9), Cancer Immunotherapy and Biomarkers(6), Brain Metastases and Treatment(6)

Publications48 total

Association Between the Volume Transfer Constant (K <sup>trans</sup> ) From Dynamic Contrast‐Enhanced Perfusion <scp>MR</scp> and <scp>HER2</scp> Status in Breast Cancer Brain Metastases
Cancer Reports·2025Open Access
Chlorotoxin-directed CAR T cell therapy for recurrent glioblastoma: Interim clinical experience demonstrating feasibility and safety
Cell Reports Medicine·2025· 3 citedOpen Access
Author Correction: Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial
Nature Medicine·2024· 6 citedOpen Access
Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial
Nature Medicine·2024· 235 citedOpen Access
Association Between 18F-FDG PET Activity and HER2 Status in Breast Cancer Brain Metastases
Nuclear Medicine and Molecular Imaging·2024· 4 citedOpen Access
1520 Phase I trial evaluating locoregionally-delivered IL13Rα2-targeting CAR T cells in high-grade glioma
2023Open Access
1525 Initial clinical experience with chlorotoxin-redirected CAR T cells for patients with recurrent glioblastoma
2023· 2 citedOpen Access
Expansion of endogenous T cells in CSF of pediatric CNS tumor patients undergoing locoregional delivery of IL13R⍺2-targeting CAR T cells: an interim analysis
2023· 15 citedOpen Access
400.2: Long-term insulin independence following allogenic islet transplant and childbirth
Transplantation·2023
Phase I Trial Evaluating Locoregionally-delivered IL13Rα2-targeting CAR T Cells in High-Grade Glioma
2023· 1 citedOpen Access
TRLS-05. PRELIMINARY RESULTS FROM A PHASE I TRIAL TO EVALUATE INTRAVENTRICULAR DELIVERY OF IL13RΑ2-TARGETING CAR T CELLS AFTER LYMPHODEPLETION IN PEDIATRIC BRAIN TUMORS PATIENTS
Neuro-Oncology·2023· 1 citedOpen Access
Supplementary Tables S1-3 from Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8&lt;sup&gt;+&lt;/sup&gt; T Cells in Patients with Recurrent Glioblastoma
2023Open Access
Supplementary Figure S1 from Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8&lt;sup&gt;+&lt;/sup&gt; T Cells in Patients with Recurrent Glioblastoma
2023Open Access
Supplementary Figure S3 from Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8&lt;sup&gt;+&lt;/sup&gt; T Cells in Patients with Recurrent Glioblastoma
2023Open Access
Supplementary Figure S3 from Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8&lt;sup&gt;+&lt;/sup&gt; T Cells in Patients with Recurrent Glioblastoma
2023Open Access
Supplementary Figure S5 from Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8&lt;sup&gt;+&lt;/sup&gt; T Cells in Patients with Recurrent Glioblastoma
2023Open Access
Supplementary Figure S5 from Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8&lt;sup&gt;+&lt;/sup&gt; T Cells in Patients with Recurrent Glioblastoma
2023Open Access
Data from Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8&lt;sup&gt;+&lt;/sup&gt; T Cells in Patients with Recurrent Glioblastoma
2023Open Access
Supplementary Tables S1-3 from Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8&lt;sup&gt;+&lt;/sup&gt; T Cells in Patients with Recurrent Glioblastoma
2023Open Access
Data from Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8&lt;sup&gt;+&lt;/sup&gt; T Cells in Patients with Recurrent Glioblastoma
2023Open Access
page 1 of 3Next →

Frequent Co-authors

Massimo D’Apuzzo(33), Behnam Badie(33), Christine E. Brown(31), Stephen J. Forman(30), Renate Starr(28), Michael E. Barish(28), Jana Portnow(28), Julie R. Ostberg(24), Lihong Weng(21), Michael C. Jensen(21), Araceli Naranjo(20), Yubo Zhai(17), James R. Bading(17), Wen‐Chung Chang(16), Jamie L. Wagner(16), Christine Wright(16), Jamie R. Wagner(15), Julie Kilpatrick(14), Jonathan Hibbard(8), M. Suzette Blanchard(7)